Haghighat Jahromi

PSMA PET-CT has revolutionized prostate cancer imaging due to its high sensitivity, yet it is prone to false-positive findings in benign lesions such as vertebral hemangiomas [1, 2]. Atypical hemangiomas may mimic metastases, leading to unnecessary interventions. In this case, fluciclovine PET-CT confirmed the benign nature of the PSMA-expressing lesion. Studies have shown that fluciclovine PET offers superior specificity in differentiating malignant prostate lesions from benign conditions [5, 6].

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.